Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AAV vector manufacturing process design and scalability - Bending the trajectory to address vector-associated immunotoxicities

20 May 2022

Abstract excerpt

The pace and diversity of adeno-associated virus (AAV) vector based clinical trials over the last 5 years has been high, with definitive therapeutic benefits observed with the two products licensed by the US Food and Drug Administration, as well as several investigational products in pivotal trials demonstrating the paradigm-shifting potential of AAV based gene therapy for serious unmet medical needs. However,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35594866
DOI: 10.1016/j.ymthe.2022.05.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AAV vector manufacturing process design and scalability - Bending the trajectory to address vector-associated immunotoxicitiesPMID 35594866Read ↗

Revolution of AAV in Drug Discovery: From Delivery System to Clinical ApplicationSemantic proximity Read ↗

Considerations for Preclinical Safety Assessment of Adeno-Associated Virus Gene Therapy ProductsSemantic proximity Read ↗

AAV-Based Gene Therapy: Opportunities, Risks, and Scale-Up StrategiesSemantic proximity Read ↗

Quality Control Testing, Characterization and Critical Quality Attributes of Adeno‐Associated Virus Vectors Used for Human Gene TherapySemantic proximity Read ↗

Assessment of quality attributes for adeno‐associated viral vectorsSemantic proximity Read ↗

Development challenges associated with rAAV-based gene therapiesSemantic proximity Read ↗

Manufacturing of recombinant adeno-associated viral vectors for clinical trialsSemantic proximity Read ↗

Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapySemantic proximity Read ↗

Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral VectorsSemantic proximity Read ↗

Viral vector manufacturing: how to address current and future demands?Semantic proximity Read ↗

Optimization of adeno-associated viral (AAV) gene therapies vectors for balancing efficacy, longevity and safety for clinical applicationSemantic proximity Read ↗

Adeno-Associated Virus at 50: A Golden Anniversary of Discovery, Research, and Gene Therapy Success—A Personal PerspectiveSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.